



F. No. 01-02/2025-CPS(DRAP)
Government of Pakistan
Ministry of National Health Services, Regulation & Coordination
Drug Regulatory Authority of Pakistan
Prime Minister Health Complex, Park Road, Islamabad

Islamabad, the 3rd June 2025.

NOTIFICATION

Subject: PRIORITY PROCESSING OF CYSTEAMINE REGISTRATION APPLICATIONS

In light of the current non-registration status of Cysteamine and to ensure its earliest possible availability, the Drug Regulatory Authority of Pakistan (DRAP) in its 205th meeting held on 29th May 2025 has designated Cysteamine as priority drug. All registration applications for Cysteamine will be processed on priority basis, out of queue, for a period of one (1) year from the date of issuance of this notification.

2. All relevant stakeholders are requested to acknowledge this decision of DRAP and proceed accordingly to facilitate the expedited processing and availability of Cysteamine in the market.

(Ahsan Ul-Haq Athar)

Deputy Director

Communication, Publication & Stakeholder Engagement

CEO-Secretariate

Distribution: -

1. PS to CEO-DRAP, Islamabad
2. Director (PE&R), DRAP, Islamabad.
3. Director (MIS), DRAP with request to upload on DRAP official website.
4. Chairman, Pakistan Pharmaceutical Manufacturer Association (PPMA), H.No.474, St.34 I-8/2 Islamabad
5. Executive Director, Pharma Bureau, Chamber of Commerce, Talpur Road, Karachi.
6. Pakistan Chemist and Druggist Association (PCDA), Suit No.504, 5th Floor, Mashriq Center, Block 14, Gulshan e Iqbal, Karachi.
7. Office File